STAAR Surgical (NASDAQ:STAA) Given Consensus Rating of “Hold” by Brokerages

Shares of STAAR Surgical (NASDAQ:STAA) have earned a consensus rating of “Hold” from the nine research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $42.83.

A number of equities research analysts recently issued reports on STAA shares. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Tuesday. Canaccord Genuity Group dropped their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. Finally, Stephens raised shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd.

STAAR Surgical Stock Down 0.5 %

Shares of NASDAQ:STAA opened at $23.00 on Monday. STAAR Surgical has a 52-week low of $22.20 and a 52-week high of $52.68. The stock has a market cap of $1.13 billion, a P/E ratio of 52.27 and a beta of 0.63. The business has a fifty day moving average of $26.31 and a two-hundred day moving average of $32.87.

Insider Activity

In related news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock in a transaction dated Wednesday, December 18th. The shares were acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00. Following the completion of the purchase, the insider now owns 10,848,631 shares in the company, valued at approximately $263,947,192.23. The trade was a 0.21 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds have recently bought and sold shares of STAA. Granite Investment Partners LLC purchased a new stake in shares of STAAR Surgical during the second quarter worth approximately $17,237,000. Kayne Anderson Rudnick Investment Management LLC grew its holdings in STAAR Surgical by 50.1% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 592,621 shares of the medical instruments supplier’s stock worth $28,215,000 after acquiring an additional 197,717 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after purchasing an additional 172,779 shares during the last quarter. American Capital Management Inc. raised its holdings in shares of STAAR Surgical by 42.9% in the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock valued at $19,051,000 after purchasing an additional 154,037 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of STAAR Surgical by 25.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 459,655 shares of the medical instruments supplier’s stock valued at $21,884,000 after purchasing an additional 94,422 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.